(NewsDirect)
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthyspoke to Thomas Warner at Proactive's London studio afterannouncing that its partner Avion Pharmaceuticals is to launch anadaptive phase II/III clinical study on Lupuzor, the former’sdiscovery and putative treatment for systemic lupus erythematosus(SLE). McCarthy reveals the reasons for choosing the particular typeof study and explains what else investors can expect from ImmuPharmaduring 2023.
Contact Details
ProactiveUK Ltd
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.